Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

5

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

3
Last update : 13/03/2022
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Atezolizumab
2
Avelumab
1
CTLA4 blocking immunotherapy
3
Camrelizumab
1
Ipilimumab
4
Lambrolizumab
4
Nivolumab
5
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pedelizumab
1
Pembrolizumab
5
Tislelizumab
1
Tremelimumab
1
Vaccination - Immunization
2
Vaccines
3
Zimberelimab
1

Publications

Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study.
Thorax 2022 Jul;77;721-723 2022 Jul
Pleural Effusion Occurring During Lung Cancer Immunotherapy: A Challenge for the Clinician.
Archivos de bronconeumologia 2022 Feb;58;194-196 2022 Feb
Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy.
Internal medicine (Tokyo, Japan) 2021 Jun 01;60;1743-1746 2021 Jun 01
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018 Mar;24;216-218 2018 Mar
Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.
American journal of respiratory and critical care medicine 2018 Dec 01;198;1451-1453 2018 Dec 01
Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.
Acta oncologica (Stockholm, Sweden) 2018 Aug;57;1127-1128 2018 Aug
Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Dec;11;2048-2050 2016 Dec
Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Dec;11;2238-2240 2016 Dec

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies